PAICS Deficiency — Comprehensive Disease Characterization Report

Category: Mendelian (autosomal recessive inborn error of de novo purine synthesis) Report compiled 2026-09-02. Evidence source types: human clinical case reports, in vitro/enzymatic studies, structural biology, and comparison with allied de novo purine synthesis (DNPS) disorders.

Caveat on evidence base: PAICS deficiency is an ultra-rare Mendelian disorder. As of 2025 only three molecularly confirmed patients (plus one antenatally suspected sibling) have been reported worldwide, all homozygous for the same recurrent variant. Consequently, most disease-level statements rest on 1–3 individual patients (individual-patient/case-report evidence, not aggregated registry data). Where information is absent, this is stated explicitly. Many entries are extrapolated from the better-characterized allied DNPS defects (ADSL deficiency, AICA-ribosiduria/ATIC deficiency) and are flagged as such.

1. Disease Information

Overview. PAICS deficiency is an autosomal recessive inborn error of de novo purine synthesis (DNPS) caused by biallelic loss-of-function variants in the PAICS gene. PAICS encodes a bifunctional enzyme — phosphoribosylaminoimidazole carboxylase (AIR carboxylase, AIRC; EC 4.1.1.21) and phosphoribosylaminoimidazole-succinocarboxamide synthetase (SAICAR synthetase, SAICARS; EC 6.3.2.6) — that catalyzes the sixth and seventh of the ten sequential steps that convert PRPP to inosine monophosphate (IMP). Clinically the disorder manifests as a multiple congenital malformation (polymalformative) syndrome. The two index cases died in the early neonatal period; the third reported patient survived with a milder, non-lethal course and normal neurodevelopment, indicating a broader phenotypic spectrum than originally recognized (31600779; 39726239).

Key identifiers. - Gene: PAICS — HGNC:8587; NCBI Gene ID 10606; UniProt P22234; OMIM gene 172439; Ensembl ENSG00000128050. Genomic locus chr4:56,435,741–56,464,578 (GRCh38), cytoband 4q12 (verified via gnomAD). - Disease (phenotype) — VERIFIED IDENTIFIERS: MONDO:0859003; OMIM #619859 ("Phosphoribosylaminoimidazole carboxylase deficiency"); Orphanet ORPHA:633099; GARD:0026646 (all confirmed via OLS4/Monarch and HPO/JAX APIs). ICD-10: no specific code (closest E79.8 "Other specified disorders of purine and pyrimidine metabolism"); ICD-11: closest 5C55.2 (inborn errors of purine or pyrimidine metabolism). MeSH: no dedicated descriptor; indexed under "Purine-Pyrimidine Metabolism, Inborn Errors." - Note: an earlier draft cited OMIM #618121; the correct phenotype MIM is #619859. - EC numbers: 4.1.1.21 (AIRC) and 6.3.2.6 (SAICARS).

Synonyms / alternative names. - Phosphoribosylaminoimidazole carboxylase deficiency - SAICAR synthetase deficiency / AIR carboxylase deficiency - Multiple malformations syndrome, lethal, due to PAICS deficiency - Inborn error of de novo purine synthesis, PAICS type

Data provenance. Disease-level knowledge is derived from individual patient case reports (n=3), supporting enzymatic/cell-biology experiments in patient fibroblasts and recombinant protein, and CRISPR HeLa models — not from EHR-scale or registry aggregation.

2. Etiology

Primary cause (genetic). Biallelic (homozygous, in a consanguineous/founder context) pathogenic variants in PAICS, producing a hypomorphic bifunctional enzyme. All reported patients carry the homozygous missense variant NM_006452.4:c.158A>G, p.(Lys53Arg), which reduces catalytic activity (patient fibroblasts ~10% of control; recombinant enzyme ~25% of wild-type; carriers ~50%) (31600779).

Genetic risk factors. - Causal variant: PAICS c.158A>G p.(Lys53Arg) — recurrent across all reported families. - Consanguinity / recurrent European allele: the two index patients were from a consanguineous Faroe Islands family. The recurrent p.(Lys53Arg) allele (rs192831239) is a low-frequency pan-European variant (gnomAD NFE AF 0.135%), so its appearance in the unrelated French third case reflects the allele's general European frequency rather than a private founder. Consanguinity remains a strong risk factor for homozygosity, as for most recessive DNPS defects. - Modifier genes: none identified; the marked phenotypic difference (lethal vs. surviving with normal cognition) among patients homozygous for the same variant implies the existence of unknown genetic and/or environmental modifiers (39726239).

Environmental / lifestyle risk factors. None established. As a Mendelian congenital disorder, environmental exposure is not a primary driver. (Not applicable / no evidence.)

Protective factors. None documented. Heterozygous carriers (~50% residual activity) are asymptomatic, indicating ~50% enzyme activity is sufficient (haplosufficiency), consistent with recessive inheritance.

Gene–environment interactions. No data. Speculatively, dietary purine intake or salvage-pathway flux could modulate severity (as purine salvage can partly compensate for DNPS defects), but this is untested in PAICS deficiency.

3. Phenotypes

Phenotype data derive from three patients. The two Faroese siblings (31600779) had a lethal neonatal multiple-malformation presentation; the third patient (39726239) had a non-lethal polymalformative syndrome with normal neurodevelopment, expanding the spectrum.

Official curated HPO annotations with frequencies (from OMIM #619859 / HPO-JAX; frequencies reflect the 2 index siblings, n=2, unless noted). These are the authoritative phenotype associations for knowledge-base ingestion:

Additional features from the third (surviving) patient (39726239), not in the OMIM/HPO n=2 curation: congenital heart defect/cardiopathy (HP:0001627, newly described), plus preserved/normal neurodevelopment (distinguishing feature). The MONDO/OMIM narrative also lists nasal hypoplasia and lung malformations.

Phenotype characteristics. - Age of onset: congenital/neonatal (prenatal in the antenatally diagnosed sibling). - Severity: variable — lethal neonatal to survivable childhood form. - Progression: congenital and largely static (malformations fixed); the survivor showed normal neurodevelopmental trajectory. - Frequency among affected: with n=3, "frequencies" are indicative only — skeletal and oesophageal defects appear consistent (reported as a recurring theme); congenital heart disease in 1/3; early death in 2/3.

Quality-of-life impact. In the lethal form, QoL is dominated by neonatal demise. In the survivor, impact relates to surgical correction of malformations (cardiac, oesophageal, skeletal) with preserved cognition — a comparatively favourable functional outlook (39726239). No formal EQ-5D/SF-36/PROMIS data exist.

Note: Allied DNPS disorders (ADSL, ATIC) are dominated by neurological features (psychomotor retardation, epilepsy, autistic features, visual impairment) (25112391; 32557644). Notably, PAICS deficiency in the survivor spared the CNS, distinguishing it phenotypically.

4. Genetic / Molecular Information

Causal gene. PAICS (HGNC:8587; OMIM 172439; Gene ID 10606; UniProt P22234), chromosome 4q12. Encodes a 425-aa bifunctional polypeptide that assembles into a homo-octamer (17224163).

Pathogenic variant(s). - NM_006452.4:c.158A>G, p.(Lys53Arg) (= NM_001079524.2:c.158A>G) — missense; homozygous in all reported patients. ClinVar: Likely pathogenic (review status "criteria provided, multiple submitters, no conflicts", verified via NCBI eutils). Affects the structure of the enzyme's catalytic site (31600779). - PAICS has 81 ClinVar entries, overwhelmingly VUS; besides p.Lys53Arg, a truncating variant c.843_844del (p.Cys281_Glu282delinsTer) is also listed as Likely pathogenic (no published clinical report identified) — indicating additional candidate pathogenic alleles may exist beyond the recurrent founder missense. - Variant type/class: missense (single-nucleotide substitution). - Functional consequence: loss of function (hypomorph) — residual ~10–25% activity; reduces flux through both AIRC and SAICARS reactions; abolishes purinosome assembly. - Allele frequency (gnomAD v4, verified): dbSNP rs192831239; SPDI NC_000004.12:56441803:A:G (GRCh38 chr4:56,441,804 A>G); OMIM allelic variant 172439.0001; ClinGen CA2930671. Exome AC 1675 / AN 1,448,934, AF 0.116%, 0 homozygotes; genome AF 0.072%, 0 homozygotes. Ancestry: highest in non-Finnish European (0.135%), then South Asian (0.079%), Admixed American (0.070%), Finnish (0.025%), African (0.018%); absent in Ashkenazi Jewish, East Asian, Middle Eastern. → The allele is a recurrent low-frequency pan-European variant, NOT a private Faroese founder mutation; the complete absence of homozygotes (despite carrier frequency ~1/370–1/740 in Europeans) is consistent with recessive prenatal/neonatal lethality removing homozygotes from population databases (and possible under-ascertainment/reduced penetrance). - Somatic vs. germline: germline (congenital, biallelic).

gnomAD gene-level constraint (verified). PAICS is not loss-of-function-intolerant: pLI ≈ 0 (5.8×10⁻⁷), LOEUF 0.82 (oe_lof 0.61; observed/expected LoF 33/53.7), missense z = 1.92 (mild constraint). This lack of haploinsufficiency is fully consistent with autosomal recessive inheritance — a single functional allele suffices (heterozygotes are asymptomatic with ~50% activity).

ACMG considerations. p.(Lys53Arg) is classified Likely pathogenic in ClinVar (multiple submitters, no conflicts). Supporting criteria: strong functional evidence (PS3 — measured reduced enzyme activity and abolished purinosome assembly, rescued by wild-type PAICS), rarity (PM2), and recurrence across unrelated families. Beyond this founder missense, most PAICS ClinVar entries are VUS, with one additional Likely-pathogenic truncating allele (c.843_844del).

Modifier genes. None identified; presence strongly inferred from intra-genotype phenotypic variability (lethal vs. surviving).

Epigenetic information. No disease-specific methylation/chromatin data for PAICS deficiency. (In cancer biology, PAICS is subject to m6A-mediated and H3K9me3/HP1α-linked regulation of the ASB11 axis controlling purinosome assembly — 37848033, 42493545 — but this is oncologic, not germline-disease, context.)

Chromosomal abnormalities. None; PAICS deficiency is a single-gene point-mutation disorder. (In cancers, chromosome-4q loss reduces PAICS expression — 33596246 — unrelated to the Mendelian disease.)

5. Environmental Information

• Environmental factors / toxins / radiation: none implicated. (Not applicable.)
• Lifestyle factors: none implicated; congenital genetic disorder.
• Infectious agents: none; not an infectious/triggered disease.

The only "environmental" dimension of theoretical relevance is dietary purine availability and salvage-pathway substrate supply, which could in principle modulate a DNPS defect, but no evidence exists in PAICS deficiency.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Homozygous PAICS c.158A>G (p.Lys53Arg) alters the catalytic-site structure of the bifunctional AIRC/SAICARS enzyme → leads to reduced catalytic activity (~10–25% residual) [demonstrated: enzyme assays, 31600779].
2. Reduced PAICS activity results in a block at steps 6–7 of de novo purine synthesis (AIR → CAIR → SAICAR) → impaired conversion toward IMP [demonstrated biochemically in DNPS defects; 35323684].
3. The mutant PAICS fails to nucleate the purinosome (the multi-enzyme DNPS metabolon); purinosome assembly is abolished and is rescued only by wild-type PAICS [demonstrated in patient fibroblasts, 31600779; PAICS is a hub of purinosome protein–protein interactions, 35331738].
4. Loss of channeled DNPS leads to two downstream, non-exclusive insults:
5. (4a) Purine nucleotide insufficiency → reduced supply of AMP/GMP/ATP/GTP for nucleic-acid synthesis and energy/signaling → impaired proliferation during rapid embryonic morphogenesis → congenital malformations [inferred].
6. (4b) Accumulation of upstream intermediates (predicted AIR/CAIR; their dephosphorylated ribosides, e.g., AIr) → cytotoxicity (AIr shown cytotoxic to multiple cell lines) → cell death/dysmorphogenesis [partly demonstrated: AIr toxicity, 31600779; analogous to SAICAr/S-Ado toxicity in ADSL and AICA-riboside toxicity in ATIC deficiency, 25112391, 32557644].
7. Tissue-level consequences during organogenesis result in structural defects of the skeleton, oesophagus (foregut), and heart, plus growth restriction and dysmorphism → the polymalformative syndrome; where the insult is severe, early neonatal death [observed, 31600779; 39726239].
8. Branch point: with only partial enzyme loss and/or protective modifiers, purine supply may be sufficient postnatally to permit survival with normal neurodevelopment (third patient) — the CNS may be relatively spared compared with ADSL/ATIC defects [observed, 39726239; mechanism of sparing inferred].

Molecular pathways. De novo purine biosynthesis (KEGG hsa00230 purine metabolism; Reactome "Purine ribonucleoside monophosphate biosynthesis"). PAICS catalyzes: AIR + CO₂ → CAIR (AIRC, EC 4.1.1.21) and CAIR + L-aspartate + ATP → SAICAR (SAICARS, EC 6.3.2.6).

Cellular processes. Metabolon (purinosome) assembly/phase separation; nucleotide biosynthesis; cell proliferation; apoptosis (from intermediate cytotoxicity). GO suggestions: GO:0006189 ('de novo' IMP biosynthetic process), GO:0009152 (purine ribonucleotide biosynthetic process), GO:0034023 (purinosome — as protein complex/assembly context), GO:0004638 (phosphoribosylaminoimidazole carboxylase activity), GO:0004639 (phosphoribosylaminoimidazolesuccinocarboxamide synthase activity).

Protein dysfunction. p.Lys53Arg is a loss-of-function/hypomorphic substitution distorting the catalytic site; the enzyme normally functions only as an octamer with substrate-channeling tunnels between AIRC and SAICARS active sites (17224163; 32571877; reaction mechanism, 35914774). Loss of activity + loss of purinosome-nucleating protein–protein interactions (35331738). Experimental structures (RCSB PDB): 2H31 (octameric apo structure, 17224163), 6YB8 / 6YB9 (substrate/product complexes, 32571877), 7ALE; UniProt P22234; AlphaFold model AF-P22234-F1. Residue Lys53 lies in the AIR-carboxylase domain near the catalytic site.

Metabolic changes. Amino-acid/nucleotide metabolism: reduced IMP→AMP/GMP; predicted accumulation of AIR/CAIR/ SAICAR and their ribosides (CHEBI: aminoimidazole ribotide/AIR; SAICAR). Metabolomic profiling of DNPS-deficient HeLa cells shows accumulation of intermediates immediately upstream of the deficient enzyme (35323684).

Immune involvement. None described (not an immunologic disease).

Tissue-damage mechanisms. Cytotoxicity of accumulated dephosphorylated intermediates; nucleotide starvation of proliferating cells.

Molecular profiling. CRISPR-Cas9 PAICS-knockout/deficient HeLa cells provide targeted + untargeted metabolomic signatures of the DNPS block (35323684, 35331738). No patient transcriptomic/proteomic/metabolomic datasets published beyond fibroblast enzymology.

Cell types & GO/CL suggestions. Fibroblasts used experimentally (CL:0000057). In vivo affected cell populations are rapidly proliferating embryonic progenitors of skeletal (CL:0000062 osteoblast; CL:0000138 chondrocyte), cardiac (CL:0000746 cardiac muscle cell), and foregut/oesophageal epithelium (CL:0000066 epithelial cell) — inferred from malformation pattern.

7. Anatomical Structures Affected

Organ level (primary): skeleton (UBERON:0001434 skeletal system), oesophagus (UBERON:0001043), heart (UBERON:0000948). Growth (whole-body/UBERON multi-organ). Secondary: consequences of malformations (e.g., feeding/airway from oesophageal defects; circulatory from cardiac defects).

Body systems: musculoskeletal, digestive (foregut), cardiovascular; generalized growth. CNS relatively spared in the survivor (contrast with allied DNPS disorders that are CNS-dominant).

Tissue/cell level: connective/skeletal tissue (cartilage, bone), cardiac muscle, gut epithelium. CL terms as above.

Subcellular level: the purinosome is a mitochondria-associated cytoplasmic metabolon (35331738). GO cellular-component suggestions: GO:0005829 (cytosol), mitochondrial outer-membrane association; the purinosome itself is a dynamic, membraneless (phase-separated) body (37848033).

Localization / lateralization: malformations are congenital and can be midline/bilateral (skeletal, cardiac, oesophageal); no consistent lateralization reported (n too small).

8. Temporal Development

• Onset: congenital; detectable antenatally (a suspected sibling recurrence was diagnosed prenatally, 39726239). Onset pattern: chronic/congenital (present from organogenesis).
• Progression / course: malformations are structurally fixed. In the lethal form, course is acute neonatal deterioration → death within days (31600779). In the surviving form, course is stable post-surgical correction with normal developmental trajectory to at least 7 years (39726239).
• Disease duration: lethal (self-limited by neonatal death) vs. chronic/lifelong in survivors.
• Critical periods: first-trimester organogenesis is the window of vulnerability (skeletal/foregut/cardiac morphogenesis). Prenatal detection offers a window for counseling; no fetal/neonatal metabolic intervention is established.

9. Inheritance and Population

• Inheritance: autosomal recessive (biallelic PAICS variants; heterozygous parents asymptomatic).
• Epidemiology: ultra-rare; prevalence/incidence unknown (<1/1,000,000; only 3 reported cases). No registry data.
• Penetrance: appears complete for the malformation phenotype in homozygotes, but expressivity is highly variable (lethal neonatal vs. surviving with normal cognition) despite the identical genotype (39726239).
• Expressivity: variable (see above).
• Genetic anticipation: not applicable (not a repeat-expansion disorder).
• Germline mosaicism: not reported.
• Founder effect / consanguinity (revised via gnomAD): the recurrent p.(Lys53Arg)/rs192831239 allele is not a private Faroese founder but a recurrent low-frequency pan-European variant (gnomAD exome AF 0.116%; highest in non-Finnish Europeans, 0.135%). Its recurrence in an unrelated French patient is therefore expected. The index family was consanguineous (Faroe Islands), which brought two copies together; consanguinity remains a risk factor for homozygosity of this and other recessive alleles.
• Carrier frequency (verified): ~1/370–1/740 in Europeans (2×AF ≈ 0.23–0.27% NFE); rarer in African, absent in Ashkenazi/East Asian/Middle Eastern gnomAD samples. Notably zero homozygotes are observed in ~1.45 million gnomAD alleles, despite an expected homozygote birth frequency on the order of ~1/550,000 (NFE) — consistent with recessive prenatal/neonatal lethality (affected individuals excluded from gnomAD) and/or reduced penetrance; implies the disorder is likely under-ascertained (unrecognized fetal losses/neonatal deaths).
• Population demographics / geography: first cases Faroe Islands; third case reported from a European (French) centre — consistent with the allele's European distribution. No sex predilection evident (both sexes affected; third patient male). Age distribution: prenatal-to-childhood onset.

10. Diagnostics

Diagnostic approach. Because DNPS-intermediate biomarkers may be undetectable (AIR/AIr were not found in patient fibroblasts, 31600779), diagnosis is primarily molecular/genomic.

• Genetic testing (primary): whole-genome sequencing (WGS) established the diagnosis in the third patient; whole-exome sequencing (WES) is equally appropriate; single-gene PAICS testing/targeted analysis of c.158A>G is useful where the founder allele is suspected. Purine-metabolism/inborn-error gene panels including PAICS are appropriate (GTR).
• Biochemical/laboratory: urine/plasma/CSF purine metabolite profiling (HPLC-MS) as used for ADSL (SAICAr, S-Ado) and ATIC (AICA-riboside) — but note classic accumulating markers may be absent in PAICS deficiency, limiting biochemical screening (31600779). Enzyme activity assay in cultured skin fibroblasts (reduced to ~10%) is confirmatory (LOINC/enzyme assay).
• Functional/cellular: purinosome-assembly assay in fibroblasts (absent, rescued by WT PAICS) — a research-grade functional confirmation.
• Imaging: prenatal/postnatal imaging (fetal ultrasound, echocardiography, skeletal survey, contrast oesophagram) to delineate malformations. RadLex terms as appropriate.
• Histopathology: no pathognomonic biopsy finding described.

Clinical criteria / differential diagnosis. No formal criteria. Differential includes other DNPS defects (ADSL deficiency, AICA-ribosiduria/ATIC, ADSS/ADSS1/2, ATIC, PRPS abnormalities) — distinguished by their CNS-dominant presentation and specific accumulating metabolites; also other polymalformative/VACTERL-spectrum syndromes (given vertebral, cardiac, oesophageal involvement) and chromosomal disorders (excluded by CMA/karyotype/sequencing).

Screening. Carrier/cascade testing for the familial p.(Lys53Arg) variant; prenatal molecular testing feasible (used in the suspected sibling). Not part of routine newborn screening.

11. Outcome / Prognosis

• Survival/mortality: in the index family, 2/2 siblings died in the early neonatal period (31600779). The third patient survived to at least 7 years with normal neurodevelopment (39726239). Thus prognosis is bimodal/variable, ranging from neonatal-lethal to survivable childhood disease.
• Morbidity/function: in survivors, morbidity is driven by structural malformations requiring surgical correction (cardiac, oesophageal, skeletal); cognition may be preserved, an important prognostic distinction from ADSL/ATIC deficiencies.
• Complications: those of congenital heart disease, oesophageal malformation (feeding/respiratory), and skeletal anomalies.
• Prognostic factors: severity/number of malformations and (inferred) residual enzyme function/modifiers determine lethality. The 2025 report explicitly updated prognosis to include the possibility of survival with normal neurodevelopment (39726239).
• QoL measures: none formally applied.

12. Treatment

No disease-specific/curative therapy exists. Management is supportive and symptomatic (NCIT: Supportive Care Therapy; NCIT:C15277 Supportive Care).

• Pharmacotherapy: none targeted; there is no established purine-replacement therapy for PAICS deficiency. (Theoretical strategies — dietary/purine salvage support, avoidance of intermediate accumulation — are unproven.)
• Surgical/interventional: correction of congenital malformations (cardiac surgery, oesophageal repair, orthopedic management) in survivors (NCIT clinical-intervention terms as applicable, e.g., Cardiac Surgery, Esophageal repair).
• Supportive/rehabilitative: neonatal intensive care; nutritional support; multidisciplinary follow-up.
• Advanced/experimental therapeutics: none in trials for PAICS deficiency. Gene therapy, enzyme replacement, or substrate-modulation approaches are conceptual only. (Note: PAICS is being pursued as an oncology drug target — inhibitors to reduce purine synthesis in cancer — 37673296, 34344987 — the opposite therapeutic direction from this deficiency.)
• Pharmacogenomics: not applicable.
• Treatment outcomes / adverse events: determined by surgical/critical-care outcomes; no drug outcome data.

13. Prevention

• Primary prevention: genetic counseling for consanguineous families and known carriers; carrier/cascade screening for the familial p.(Lys53Arg) allele; reproductive options including preimplantation genetic testing (PGT) and prenatal molecular diagnosis (feasible, as demonstrated antenatally in the suspected sibling, 39726239).
• Secondary prevention: prenatal imaging + molecular testing enables early detection and delivery planning; early surgical correction of malformations in survivors.
• Tertiary prevention: management of complications of congenital malformations.
• Immunization / public-health / environmental interventions: not applicable (Mendelian disorder).
• Counseling: recurrence risk 25% per pregnancy for carrier couples (autosomal recessive); NSGC/ACMG genetic-counseling frameworks apply.

14. Other Species / Natural Disease

• Taxonomy / orthologs (verified via Alliance of Genome Resources, stringent): PAICS is deeply conserved across metazoa and fungi. One-to-one/many orthologs:
• Mouse Paics — MGI:1914304; NCBI Gene 67054; NCBITaxon:10090
• Rat Paics — RGD:620066; NCBITaxon:10116
• Zebrafish paics — ZFIN:ZDB-GENE-030131-9762; NCBITaxon:7955
• Drosophila melanogaster Paics — FB:FBgn0020513; NCBITaxon:7227
• Caenorhabditis elegans paic-1 — WB:WBGene00015116; NCBITaxon:6239
• Saccharomyces cerevisiae ADE1 — SGD:S000000070; NCBITaxon:4932 (note: yeast splits the bifunctional activity — ADE1 = SAICAR synthetase, ADE2 = AIR carboxylase)
• Xenopus tropicalis/laevis paics — Xenbase
• Bacterial functional homologs: PurC/PurE/PurK. DNPS is among the most conserved biosynthetic pathways.
• Natural disease in other species: no naturally occurring PAICS-deficiency disease is catalogued in OMIA for companion animals/livestock (none found — verify).
• Comparative biology: the octameric bifunctional vertebrate PAICS contrasts with separate monofunctional bacterial/yeast enzymes; substrate channeling and purinosome assembly are conserved features studied to understand human disease.
• Zoonotic/cross-species transmission: not applicable (genetic, non-transmissible).

15. Model Organisms

• Cellular / in vitro models (principal): CRISPR-Cas9 PAICS-knockout / deficient HeLa cells used for targeted + untargeted metabolomic profiling of the DNPS block (35323684) and for dissecting purinosome protein–protein interactions and metabolic channeling (crPAICS cells, 35331738). Patient skin fibroblasts (primary) recapitulate reduced enzyme activity and absent purinosome assembly, rescued by wild-type PAICS transfection (31600779).
• Recombinant enzyme: E. coli-expressed wild-type and p.Lys53Arg PAICS for kinetic characterization (31600779); human PAICS crystal structures for mechanistic/structural study (17224163, 32571877, 35914774).
• Genetic model types available: knockout/knockdown cell lines (CRISPR, shRNA — the latter widely used in cancer studies, e.g., AML, 34344987).
• Mouse Paics knockout (IMPC, verified via IMPC solr): homozygous null mice show "preweaning lethality, complete penetrance" and "prenatal lethality prior to heart atrial septation" (homozygote, complete penetrance) — i.e., Paics is an essential gene and complete loss is embryonically/prenatally lethal. No viable homozygous-null adults. Suggested MP terms: MP:0011100 (preweaning lethality, complete penetrance), prenatal-lethality MP terms. This is mechanistically important: it explains why human patients carry a hypomorphic missense (p.Lys53Arg, ~10–25% residual activity) rather than biallelic nulls, and the "prenatal lethality prior to heart atrial septation" parallels the congenital cardiac defect in the surviving human patient (39726239).
• Phenotype recapitulation: cell models reproduce the biochemical/purinosome defect well; the mouse null recapitulates lethality/essentiality but (being a complete null) does not model the hypomorphic human malformation syndrome. Limitation: no published hypomorphic/knock-in Paics animal model (e.g., p.Lys53Arg knock-in) recapitulating the human polymalformative phenotype exists (gap / future direction).
• Resources: Cellosaurus (HeLa derivatives), MGI/IMPC (mouse Paics), ZFIN (zebrafish paics) for reagents.

Key Ontology Term Suggestions (summary)

• Gene/protein: PAICS (HGNC:8587, UniProt P22234); GO:0004638, GO:0004639, GO:0006189, GO:0009152.
• Phenotypes (HPO): HP:0002011/HP:0001263 (malformation), HP:0003811 (neonatal death), HP:0002032 (esophageal atresia), HP:0001627 (abnormal heart morphology), HP:0000924 (skeletal abnormality), HP:0001999 (facial dysmorphism), HP:0001511 (IUGR).
• Cell types (CL): CL:0000057 (fibroblast), CL:0000062 (osteoblast), CL:0000138 (chondrocyte), CL:0000746 (cardiomyocyte), CL:0000066 (epithelial cell).
• Anatomy (UBERON): UBERON:0001434 (skeletal system), UBERON:0001043 (esophagus), UBERON:0000948 (heart).
• Chemicals (CHEBI): AIR/aminoimidazole ribotide, CAIR, SAICAR, IMP; substrate CO₂, L-aspartate, ATP.
• Disease (MONDO/OMIM): MONDO:0859003; OMIM #619859; Orphanet ORPHA:633099; GARD:0026646 (all verified).
• Treatment (NCIT): supportive care; surgical repair of congenital anomalies.

Supported vs. Refuted Statements

Supported (evidence-based): - PAICS deficiency is AR, caused by biallelic PAICS p.(Lys53Arg); loss-of-function reduces enzyme activity and abolishes purinosome assembly (31600779). (Strong: enzymatic + cellular rescue.) - Phenotype = congenital multiple-malformation syndrome; spectrum spans neonatal-lethal to survivable-with-normal-cognition (31600779, 39726239). (Moderate: n=3.) - Accumulating intermediate ribosides (AIr) are cytotoxic; analogous to other DNPS defects (31600779; 25112391; 32557644). (Moderate.)

Refuted / not supported: - That classic urinary DNPS metabolite markers reliably diagnose PAICS deficiency — refuted: predicted markers were undetectable in patient fibroblasts; molecular testing is required (31600779). - That PAICS deficiency is uniformly CNS-degenerative like ADSL/ATIC — not supported: the survivor had normal neurodevelopment (39726239).

Limitations & Future Directions

• Evidence rests on 3 patients with the same variant; genotype–phenotype breadth, penetrance, carrier frequency, and epidemiology are essentially unknown.
• No validated whole-animal disease model; mechanism of malformation (nucleotide starvation vs. intermediate toxicity) not fully resolved for organogenesis.
• Priorities: identify additional patients/variants; establish biomarker(s); build animal models; test whether purine-salvage support alters outcome; clarify modifiers explaining lethal-vs-survivable divergence.

Prepared for disease knowledge-base population. Verified against primary databases: disease identifiers (MONDO:0859003, OMIM #619859, ORPHA:633099, GARD:0026646) via OLS4/Monarch; HPO annotations via HPO-JAX; variant classification (ClinVar VCV001686821, Likely pathogenic) and coordinates (rs192831239, chr4:56,441,804 GRCh38) via NCBI eutils; allele frequency (gnomAD v4 exome AF 0.116%, 0 homozygotes) and gene constraint via gnomAD API; orthologs via Alliance of Genome Resources; mouse-knockout lethality via IMPC; PDB structures via RCSB. Remaining items to confirm before ingestion: exact OMIA status (no natural animal disease found), and any newer case reports post-2025.